- Home
- HFBL vs LPCN Comparison
HFBL vs LPCN Comparison
Compare HFBL & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFBL
- LPCN
- Stock Information
- Founded
- HFBL 1924
- LPCN 1997
- Country
- HFBL United States
- LPCN United States
- Employees
- HFBL N/A
- LPCN N/A
- Industry
- HFBL Savings Institutions
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- HFBL Finance
- LPCN Health Care
- Exchange
- HFBL Nasdaq
- LPCN Nasdaq
- Market Cap
- HFBL 39.4M
- LPCN 36.8M
- IPO Year
- HFBL N/A
- LPCN N/A
- Fundamental
- Price
- HFBL $12.89
- LPCN $4.87
- Analyst Decision
- HFBL
- LPCN Strong Buy
- Analyst Count
- HFBL 0
- LPCN 1
- Target Price
- HFBL N/A
- LPCN $10.00
- AVG Volume (30 Days)
- HFBL 3.2K
- LPCN 33.5K
- Earning Date
- HFBL 01-23-2025
- LPCN 11-07-2024
- Dividend Yield
- HFBL 4.03%
- LPCN N/A
- EPS Growth
- HFBL N/A
- LPCN N/A
- EPS
- HFBL 1.09
- LPCN N/A
- Revenue
- HFBL $19,727,000.00
- LPCN $7,922,926.00
- Revenue This Year
- HFBL N/A
- LPCN N/A
- Revenue Next Year
- HFBL N/A
- LPCN N/A
- P/E Ratio
- HFBL $11.87
- LPCN N/A
- Revenue Growth
- HFBL N/A
- LPCN N/A
- 52 Week Low
- HFBL $10.60
- LPCN $2.44
- 52 Week High
- HFBL $14.80
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- HFBL 55.93
- LPCN 47.54
- Support Level
- HFBL $12.55
- LPCN $4.68
- Resistance Level
- HFBL $13.14
- LPCN $5.28
- Average True Range (ATR)
- HFBL 0.22
- LPCN 0.36
- MACD
- HFBL 0.04
- LPCN -0.01
- Stochastic Oscillator
- HFBL 67.82
- LPCN 44.44
About HFBL Home Federal Bancorp Inc. of Louisiana
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.